Early OCTA Changes of Type 3 Macular Neovascularization Following Brolucizumab Intravitreal Injections.
Anthony GigonMaria VadalàVincenza M E BonfiglioMichele ReibaldiChiara M EandiPublished in: Medicina (Kaunas, Lithuania) (2022)
Brolucizumab IVI shows a good short-term efficacy for the treatment of type 3 neovascularizations. Further studies with greater number of patients and longer follow-up are warranted to confirm these findings.
Keyphrases
- diabetic retinopathy
- end stage renal disease
- vascular endothelial growth factor
- ejection fraction
- newly diagnosed
- prognostic factors
- optical coherence tomography
- age related macular degeneration
- patient reported outcomes
- patient reported
- endothelial cells
- ultrasound guided
- platelet rich plasma
- replacement therapy